Last reviewed · How we verify
NCT06953765
A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer
trial testing PSQI in Lung Cancer (NSCLC) in 350 participants. Not yet recruiting.
30 December 2028
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 350 |
| Start date | 1 June 2025 |
| Primary completion | 30 December 2028 |
| Estimated completion | 30 December 2028 |
Drugs / interventions tested
- PSQI
- PQSI
Conditions studied
- Lung Cancer (NSCLC) — all drugs for Lung Cancer (NSCLC) →
- Sleep Disorders, Circadian Rhythm — all drugs for Sleep Disorders, Circadian Rhythm →
- PD-1 — all drugs for PD-1 →
Sponsor
Shanghai Zhongshan Hospital
Who can join
Adults 18 to 70, any sex, with Lung Cancer (NSCLC) or Sleep Disorders, Circadian Rhythm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In recent years, immunotherapy has made significant progress in the treatment of lung cancer, especially immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies) against non-small cell lung cancer (NSCLC). However, there are significant individual differences in patient response to treatment. Studies have shown that sleep disorders may affect the function of the immune system, thereby affecting tumor progression and treatment response. Therefore, the aim of this study was to evaluate the impact of sleep disturbances on lung cancer patients receiving immunotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06953765
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PSQI
Trials testing the same drug.
- NCT06941948 — Sleep Disorders and Tumor Immune Microenvironment · recruiting
- NCT04549350 — Sleep Quality Among HCWs · completed
- NCT03773601 — Objective Sleep Behavior in Relation to a Nigth Competition in Athletes. · NA · completed
- NCT06953492 — Sleep State in Lung Cancer: A Retrospective Analysis · completed
Other recruiting trials for Lung Cancer (NSCLC)
Currently open trials in the same condition.
- NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
- NCT07379476 — Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer · Phase 2 · recruiting
- NCT07103395 — A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade · Phase 2 · recruiting
- NCT06717295 — The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cel · recruiting
- NCT07120282 — Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC · Phase 2 · recruiting
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06953765 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 1 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06953765.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing